Login Get Started
Browse Breadcrumb chevron Shares Breadcrumb chevron Healthcare Breadcrumb chevron Biotechnology & Medical Research Breadcrumb chevron Aprea Therapeutics Inc
Aprea Therapeutics Inc logo

APRE - Aprea Therapeutics Inc Reuters News

$4.46 -0.2  -4.1%

Last Trade - 19/04/21

Sector
Healthcare
RiskRating
Speculative
Size
Small Cap
Style
Sucker Stock
Market Cap £67.6m
Enterprise Value £3.92m
Revenue £n/a
Position in Universe 5181st / 6849
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions APRE Dividends
Reuters News
All News Reuters News Company Announcements
Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
12th Dec '19 News
Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
9th Dec '19 News
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
9th Dec '19 News
BRIEF-Aprea Therapeutics Inc Qtrly Net Loss Per Share, Basic And Diluted $5.29
14th Nov '19 News
Aprea Therapeutics Reports Third Quarter 2019 Financial Results
14th Nov '19 News
Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting
6th Nov '19 News
BRIEF-Versant Ventures V Llc Reports 12.1% Passive Stake In Aprea Therapeutics As Of October 7 - SEC Filing
18th Oct '19 News
BRIEF-Healthcap Vii Lp Reports 11.9 % Stake In Aprea Therapeutics
18th Oct '19 News
BRIEF-Andrew J. Schwab Reports 13.8% Stake In Aprea Therapeutics Inc As Of Oct 7, 2019
17th Oct '19 News
Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
7th Oct '19 News
LIVE MARKETS U.S.-Trio of biotechs cross finish line, ADC falls short amid IPO anxiety
3rd Oct '19 News
BUZZ-Aprea Therapeutics: Trading high after debut on Nasdaq
3rd Oct '19 News
BRIEF-Aprea Therapeutics Shares Debut about 3.1% over IPO price
3rd Oct '19 News
NASDAQ RESUMED
3rd Oct '19 News
NASDAQ TRADE HALT REASON NOT AVAILABLE
3rd Oct '19 News
BRIEF-Aprea Therapeutics Announced Pricing Of Its IPO Of 5.7 Mln Shares At $15.00 Per Shr
3rd Oct '19 News
Aprea Therapeutics Announces Pricing of Initial Public Offering
3rd Oct '19 News
Biotechnology firm ADC pulls listing amid latest IPO market jitters
3rd Oct '19 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.